The roles of nerve growth factor and cholecystokinin in the enhancement of morphine analgesia in a rodent model of central nervous system inflammation

Neuropharmacology

Volumn 56, Issue 3, 2009, Pages 684-691

  Xanthos, Dimitris N ^a,b   Kumar, Naresh ^a,b   Theodorsson, Elvar ^d   Coderre, Terence J ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cholecystokinin; CNS inflammation; In vivo microdialysis; Lipopolysaccharide; Nerve growth factor; Spinal cord; Thermal hyperalgesia

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; LIPOPOLYSACCHARIDE; LY 225910; MORPHINE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NERVE GROWTH FACTOR BETA SUBUNIT; NEUROTROPHIC FACTOR; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IN VIVO STUDY; INFLAMMATION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALGESICS; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CHOLECYSTOKININ; DISEASE MODELS, ANIMAL; INFLAMMATION; INJECTIONS, SPINAL; LIPOPOLYSACCHARIDES; MALE; MORPHINE; NERVE GROWTH FACTOR; RATS; RATS, LONG-EVANS; SINCALIDE; SPINAL CORD;

EID: 58749098383     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.12.002     Document Type: Article

References (67)

1. de Araujo Lucas G., Alster P., Brodin E., and Wiesenfeld-Hallin Z. Differential release of cholecystokinin by morphine in rat spinal cord. Neuroscience Letters 245 (1998) 13-16
2. Bowles W.R., Sabino M., Harding-Rose C., and Hargreaves K.M. Nerve growth factor treatment enhances release of immunoreactive calcitonin gene-related peptide but not substance P from spinal dorsal horn slices in rats. Neuroscience Letters 363 (2004) 239-242
3. Cahill C.M., Dray A., and Coderre T.J. Priming enhances endotoxin-induced thermal hyperalgesia and mechanical allodynia in rats. Brain Research 808 (1998) 13-22
4. Cahill C.M., Dray A., and Coderre T.J. Enhanced thermal antinociceptive potency and anti-allodynic effects of morphine following spinal administration of endotoxin. Brain Research 960 (2003) 209-218
5. Cahill C.M., Dray A., and Coderre T.J. Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain. Neuropharmacology 45 (2003) 543-552
6. Cesselin F. Opioid and anti-opioid peptides. Fundamental and Clinical Pharmacology 9 (1995) 409-433
7. Christensen M.D., and Hulsebosch C.E. Spinal cord injury and anti-NGF treatment results in changes in CGRP density and distribution in the dorsal horn in the rat. Experimental Neurology 147 (1997) 475-483
8. Clark A.K., D'Aquisto F., Gentry C., Marchand F., McMahon S.B., and Malcangio M. Rapid co-release of interleukin 1β and caspase 1 in spinal cord inflammation. Journal of Neurochemistry 99 (2006) 868-880
9. Crawley J.N., and Corwin R.L. Biological actions of cholecystokinin. Peptides 15 (1994) 731-755
10. Djouhri L., Dawbarn D., Robertson A., Newton R., and Lawson S.N. Time course and nerve growth dependence of inflammation-induced alterations in electrophysiological membrane properties in nociceptive primary afferent neurons. Journal of Neuroscience 21 (2001) 8722-8733
11. Dourish C.T., O'Neill M.F., Coughlan J., Kitchener S.J., Hawley D., and Iversen S.D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. European Journal of Pharmacology 76 (1990) 35-44
12. Faris P.L., Komisaruk B.R., Watkins L.R., and Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219 (1983) 310-312
13. Fink H., Rex A., Voits M., and Voigt J.P. Major biological actions of CCK-a critical evaluation of research findings. Experimental Brain Research 123 (1998) 77-83
14. Friedrich A.E., and Gebhart G.F. Effects of spinal cholecystokinin receptor antagonists on morphine antinociception in a model of visceral pain in the rat. Journal of Pharmacology and Experimental Therapeutics 292 (2000) 538-544
15. Fukazawa Y., Maeda T., Kiguchi N., Tohya K., Kimura M., and Kishioka S. Activation of spinal cholecystokinin and neurokinin-1 receptors is associated with the attenuation of intrathecal morphine analgesia following electroacupuncture stimulation in rats. Journal of Pharmacological Sciences 104 (2007) 159-166
16. Gall C., Lauterborn J., Burks D., and Seroogy K. Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Research 403 (1987) 403-408
17. Gustafsson H., Afrah A., Brodin E., and Stiller C.O. Pharmacological characterization of morphine-induced in vivo release of cholecystokinin in rat dorsal horn: effects of ion channel blockers. Journal of Neurochemistry 73 (1999) 1145-1154
18. Gustafsson H., de Araujo Lucas G., Schott E., Stiller C.O., Alster P., Wiesenfeld-Hallin Z., and Brodin E. Measurement of cholecystokinin release in vivo in the rat spinal dorsal horn. Brain Research Protocols 4 (1999) 192-200
19. Gustafsson H., Lucas G.A., Schött E., Stiller C.O., Alster P., Wiesenfeld-Hallin Z., and Brodin E. Peripheral axotomy influences the in vivo release of cholecystokinin in the spinal cord dorsal horn - possible involvement of cholecystokinin-B receptors. Brain Research 790 (1998) 141-150
20. Hargreaves K., Dubner R., Brown F., Flores C., and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1988) 77-88
21. Hökfelt T., Zhang X., and Wiesenfeld-Hallin Z. Messenger plasticity in primary sensory neurons following axotomy and its functional implication. Trends in Neurosciences 17 (1994) 22-30
22. Hylden J.L., Thomas D.A., Iadarola M.J., Nahin R.L., and Dubner R. Spinal opioid analgesic effects are enhanced in a model of unilateral inflammation/hyperalgesia: possible involvement of noradrenergic mechanisms. European Journal of Pharmacology 194 (1991) 135-143
23. Ji R.R., Zhang Q., Law P.Y., Low H.H., Elde R., and Hökfelt T. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. Journal of Neuroscience 15 (1995) 8156-8166
24. Jongsma Wallin H., Danielsen N., Johnston J.M., Gratto K.A., Karchewski L.A., and Verge V.M.K. Exogenous NT-3 and NGF differentially modulate PACAP expression in adult sensory neurons, suggesting distinct roles in injury and inflammation. European Journal of Neuroscience 14 (2001) 267-274
25. Joris J., Costello A., Dubner R., and Hargreaves K.M. Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain 43 (1990) 95-103
26. Kayser V., and Guilbaud G. The analgesic effects of morphine, but not those of enkephalinase-inhibitor thiorphan, are enhanced in arthritic rats. Brain Research 267 (1983) 131-138
27. Kehl L.J., Kovacs K.J., and Larson A.A. Tolerance develops to the effect of lipopolysaccharides on movement-evoked hyperalgesia when administered chronically by a systemic route but not an intrathecal route. Pain 111 (2004) 104-115
28. Kohno T., Ji R.-R., Ito N., Allchorne A.J., Befort K., Karchewski L.A., and Woolf C.J. Peripheral axonal injury results in reduced μ opioid receptor pre- and post-synaptic action in the spinal cord. Pain 117 (2005) 77-87
29. Lewin G.R., and Mendell L.M. Nerve growth factor and nociception. Trends in Neurosciences 16 (1993) 353-358
30. Malcangio M., Garrett N.E., and Tomlinson D.R. Nerve growth factor treatment increases stimulus-evoked release of sensory neuropeptides in the rat spinal cord. European Journal of Neuroscience 9 (1997) 1101-1104
31. Malcangio M., Ramer M.S., Boucher T.J., and McMahon S.B. Intrathecally injected neurotrophins and the release of substance P from the rat isolated spinal cord. European Journal of Neuroscience 12 (2000) 139-144
32. Manni L., Lundeberg T., Tirassa P., and Aloe L. Role of cholecystokinin-8 in nerve growth factor and nerve growth factor mRNA expression in carrageenan-induced joint inflammation in adult rats. Rheumatology 41 (2002) 787-792
33. Manni L., and Lundeberg T. Effects of cholecystokinin-8 in peripheral neuropathies: a nerve growth factor mediated action?. Archives of Italian Biology 141 (2003) 117-126
34. McCleane G. Cholecystokinin antagonists: a new way to improve the analgesia from old analgesics. Current Pharmaceutical Design 10 (2004) 303-314
35. 2+ currents in rat sensory neurons. Neuroscience 125 (2004) 1029-1037
36. McMahon S.B., Bennett D.L., Priestley J.V., and Shelton D.L. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgF fusion molecule. Nature Medicine 1 (1995) 774-780
37. McMahon S.B. NGF as a mediator of inflammatory pain. Philosophical Transactions of the Royal Society of London B: Biological Sciences 351 (1996) 431-440
38. Meller S., Dykstra C., Grzybycki D., Murphy S., and Gebhart G.F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 33 (1994) 1471-1478
39. Mollereau C., Roumy M., and Zajac J.M. Opioid-modulating peptides: mechanisms of action. Current Topics in Medicinal Chemistry 5 (2005) 341-355
40. Molliver D.C., Lindsay J., Albers K.M., and Davis B.M. Overexpression of NGF or GDNF alters transcriptional plasticity evoked by inflammation. Pain 113 (2005) 277-284
41. Mousa S.A., Cheppudira B.P., Shaqura M., Fischer O., Hofmann J., Hellweg R., and Schäfer M. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain. Brain 130 (2007) 502-513
42. Nichols M.L., Bian D., Ossipov M.H., Lai J., and Porreca F. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats. Journal of Pharmacology and Experimental Therapeutics 5 (1995) 1339-1345
43. Pezet S., Onteniente B., Jullien J., Junier M.P., Grannec G., Rudkin B.B., and Calvino B. Differential regulation of NGF receptors in primary sensory neurons by adjuvant-induced arthritis in the rat. Pain 90 (2001) 113-125
44. Pogatzki E.M., Zahn P.K., and Brennan T.J. Lumbar catheterization of the subarachnoid space with a 32-gauge polyurethane catheter in the rat. European Journal of Pain 4 (2000) 111-113
45. Ramer M.S., Bradbury E.J., and McMahon S.B. Nerve growth factor induces P2X(3) expression in sensory neurons. Journal of Neurochemistry 77 (2001) 864-875
46. Reeve A., Patel S., Fox A., Walker K., and Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. European Journal of Pain 4 (2000) 247-257
47. Rehfeld J.F. Immunochemical studies on cholecystokinin: I. Development of sequence-specific radioimmunoassays for porcine triacontatriapeptide cholecystokinin. Journal of Biological Chemistry 253 (1978) 4016-4021
48. Safieh-Garabedian B., Poole S., Allchorne A., Winter J., and Woolf C.J. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. British Journal of Pharmacology 115 (1995) 1265-1275
49. Shadiack A.M., Sun Y., and Zigmond R.E. Nerve growth factor antiserum induces axotomy-like changes in neuropeptide expression in intact sympathetic and sensory neurons. Journal of Neuroscience 21 (2001) 363-371
50. Skilling S.R., Smullin D.H., Beitz A.J., and Larson A.A. Extracellular amino acid concentrations in the dorsal spinal cord of freely moving rats following veratridine and nociceptive stimulation. Journal of Neurochemistry 51 (1988) 127-132
51. Stanfa L.C., Sullivan A.F., and Dickenson A.H. Alterations in neuronal excitability and potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation. Pain 50 (1992) 245-254
52. Stanfa L.C., and Dickenson A.H. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenan inflammation. British Journal of Pharmacology 108 (1993) 967-973
53. Stein C., Machelska H., Binder W., and Schafer M. Peripheral opioid analgesia. Current Opinion in Pharmacology 1 (2001) 62-65
54. Tanazawa T., Suzuki Y., Anzai M., Tsugane S., Takauasu M., and Shibuya M. Vasodilation by intrathecal lipopolysaccharide of the cerebral arteries after subarachnoid haemorrhage in dogs. Acta Neurochirurgica 138 (1996) 330-337
55. Tirassa P., Stenfors C., Lundeberg T., and Aloe L. Cholecystokinin-8 regulation of NGF concentrations in adult mouse brain through a mechanism involving CCK(A) and CCK(B) receptors. British Journal of Pharmacology 123 (1998) 1230-1236
56. Torrents D., Torres R., De Mora F., and Vergara P. Antinerve growth factor treatment prevents intestinal dysmotility in Trichinella spiralis-infected rats. Journal of Pharmacology and Experimental Therapeutics 302 (2002) 659-665
57. Ugolini G., Marinelli S., Covaceuszach S., Cattaneo A., and Pavone F. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. PNAS 104 (2007) 2985-2990
58. Vanderah T.W., Lai J., Yamamura H.I., and Porreca F. Antisense oligodeoxynucleotide to the CCKB receptor produces naltrindole and [Leu5]enkephalin antiserum-sensitive enhancement of morphine antinociception. Neuroreport 5 (1994) 1-5
59. Verge V.M., Richardson P.M., Wiesenfeld-Hallin Z., and Hökfelt T. Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. Journal of Neuroscience 15 (1995) 2081-2096
60. Wang X.J., and Han J.S. Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa opioid receptors. Journal of Neurochemistry 55 (1990) 1379-1382
61. Wang X.J., Fan S., Ren M.F., and Han J.S. Cholecystokinin-8 suppressed 3H-etorphine binding to rat brain opiate receptors. Life Sciences 45 (1989) 117-123
62. Watkins L.R., Kinscheck I.B., and Mayer D.J. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Research 327 (1985) 169-180
63. Wiesenfeld-Hallin Z., and Xu X.J. Opioid-antiopioid interactions. In: Stein C. (Ed). Opioids in Pain Control - Basic and Clinical Aspects (1999), Cambridge University Press, Cambridge 131-142
64. Wiesenfeld-Hallin Z., Xu X.J., and Hökfelt T. The role of spinal cholecystokinin in chronic pain states. Pharmacology & Toxicology 91 (2002) 398-403
65. Woolf C.J., Safieh-Garabedian B., Ma Q.P., Crilly P., and Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62 (1994) 327-331
66. Zahn P.K., Sluka K.A., and Brennan T.J. Excitatory amino acid release in the spinal cord caused by plantar incision in the rat. Pain 100 (2002) 65-76
67. Zhang X., Lucas G.A., Elde R., Wiesenfeld-Hallin Z., and Hökfelt T. Effect of morphine on cholecystokinin and μ-opioid receptor-like immunoreactivities in rat spinal dorsal horn neurons after peripheral axotomy and inflammation. Neuroscience 95 (2000) 197-207